Needham & Company Defends Progenics (PGNX) on PDUFA Delay, Valeant Overhang
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Progenics' (PGNX) Relistor Setback Only a Speedbump - Jefferies
April 5, 2016 9:34 AM EDTJefferies analyst, Gena Wang, sees the FDA extension for Progenics Pharmaceuticals' (NASDAQ: PGNX) oral Relistor as a timing setback only. No change to Buy rating or $9 PT.
The FDA extended the PDUFA by 3mon (to July 19) for oral Relistor in opioidinduced constipation in... More
Valeant Pharma (VRX), Progenics (PGNX) PDUFA for Oral RELISTOR Extended by 3 Months
April 4, 2016 7:03 AM EDTValeant Pharmaceuticals International, Inc. (NYSE: VRX) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the Oral... More
